Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: Contributions of the soluble CD163 CSF/serum ratio to a biomarker panel

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Stilund, Morten ^a,b   Gjelstrup, Mikkel Carstensen ^b   Petersen, Thor ^a   Møller, Holger Jon ^a   Rasmussen, Peter Vestergaard ^a   Christensen, Tove ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; CXCL13 CHEMOKINE; IMMUNOGLOBULIN G; NEOPTERIN; NEUROFILAMENT PROTEIN; OSTEOPONTIN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGED; AXON; BLOOD; IMMUNOLOGY; INFLAMMATION; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AREA UNDER CURVE; AXONS; BIOMARKERS; CHEMOKINE CXCL13; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; LINEAR MODELS; MACROPHAGES; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPTERIN; OSTEOPONTIN; RECEPTORS, CELL SURFACE; ROC CURVE; YOUNG ADULT;

EID: 84928905789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119681     Document Type: Article

References (73)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002; 359(9313):1221-31. PMID: 11955556
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7 PMID: 18970977
3. Kipp M, van der Valk P, Amor S. Pathology of multiple sclerosis. CNS Neurol Disord Drug Targets. 2012; 11(5):506-17. PMID: 22583433
4. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet neurology. 2005; 4(5):281-8. PMID: 15847841
5. Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, Trentini A, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Multiple sclerosis. 2011; 17(7):838-50. doi: 10.1177/1352458511399614 PMID: 21505015
6. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiology of disease. 2009; 35(2):117-27. doi: 10.1016/j.nbd.2009.04.010 PMID: 19426803
7. Ziemann U, Wahl M, Hattingen E, Tumani H. Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. Progress in neurobiology. 2011; 95(4):670-85. doi: 10.1016/j.pneurobio.2011.04.007 PMID: 21524682
8. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. Journal of neurology. 1995; 242(2):53-8. PMID: 7707089
9. Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O, Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nature reviews Neurology. 2013; 9(5):267-76. doi: 10.1038/nrneurol.2013.41 PMID: 23528543
10. Katsavos S, Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Multiple sclerosis international. 2013; 2013:340508. doi: 10.1155/2013/340508 PMID: 23401777
11. Harris VK, Sadiq SA. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Molecular diagnosis & therapy. 2009; 13(4):225-44.
12. Avsar T, Korkmaz D, Tutuncu M, Demirci NO, Saip S, Kamasak M, et al. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis. Mult Scler. 2012; 18(8):1081-91. doi: 10.1177/1352458511433303 PMID: 22252467
13. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707-17. PMID: 10852536
14. Lieury A, Chanal M, Androdias G, Reynolds R, Cavagna S, Giraudon P, et al. Tissue remodeling in periplaque regions of multiple sclerosis spinal cord lesions. Glia. 2014; 62(10):1645-58. doi: 10.1002/glia.22705 PMID: 24910450
15. Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013; 16(9):1211-8. doi: 10.1038/nn.3469 PMID: 23872599
16. Vogel DYS, Vereyken EJF, Glim JE, Heijnen PDAM, Moeton M, van der Valk P, et al. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013; 10:35. doi: 10.1186/1742-2094-10-35 PMID: 23452918
17. Zhang Z, Zhang Z-Y, Schittenhelm J, Wu Y, Meyermann R, Schluesener HJ. Parenchymal accumulation of CD163+macrophages/microglia inmultiple sclerosis brains. J Neuroimmunol. 2011; 237(1-2):73-9. doi: 10.1016/j.jneuroim.2011.06.006 PMID: 21774995
18. Stilund M, Reuschlein AK, Christensen T, Moller HJ, Rasmussen PV, Petersen T. Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis. PloS one. 2014; 9(6):e98588. doi: 10.1371/journal.pone.0098588 PMID: 24886843
19. Galea J, Cruickshank G, Teeling JL, Boche D, Garland P, Perry VH, et al. The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage. Journal of neurochemistry. 2012; 121(5):785-92. doi: 10.1111/j.1471-4159.2012.07716.x PMID: 22380637
20. Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry Part B, Clinical cytometry. 2005; 63(1):16-22. PMID: 15624200
21. Moller HJ. Soluble CD163. Scandinavian journal of clinical and laboratory investigation. 2012; 72(1): 1-13. doi: 10.3109/00365513.2011.626868 PMID: 22060747
22. Högger P, Sorg C. Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation. Biochemical and biophysical research communications. 2001; 288(4):841-3. PMID: 11688984
23. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. The Journal of experimental medicine. 1998; 187(4):655-60. PMID: 9463416
24. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt E, et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PloS one. 2010; 5(8):e11986. doi: 10.1371/journal.pone.0011986 PMID: 20700489
25. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain: a journal of neurology. 2006; 129(Pt 1):200-11.
26. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Multiple sclerosis. 2009; 15(11):1271-9. doi: 10.1177/1352458509107017 PMID: 19805441
27. Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Multiple sclerosis. 2013; 19(9):1204-8. doi: 10.1177/1352458512473362 PMID: 23322500
28. Kowarik MC, Cepok S, Sellner J, Grummel V, Weber MS, Korn T, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation. 2012; 9:93. doi: 10.1186/1742-2094-9-93 PMID: 22591862
29. Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004; 104(10):3021-7. PMID: 15284119
30. Romme Christensen J, Bornsen L, Khademi M, Olsson T, Jensen PE, Sorensen PS, et al. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple sclerosis. 2013; 19(7):877-84. doi: 10.1177/1352458512466929 PMID: 23178691
31. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009; 73(23):2003-10. doi: 10.1212/WNL.0b013e3181c5b457 PMID: 19996075
32. Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, et al. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PloS one. 2013; 8(11):e81007. doi: 10.1371/journal.pone.0081007 PMID: 24278364
33. Ragheb S, Li Y, Simon K, VanHaerents S, Galimberti D, De Riz M, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Multiple sclerosis. 2011; 17(7):819-29. doi: 10.1177/1352458511398887 PMID: 21372118
34. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Multiple sclerosis. 2011; 17(3):335-43. doi: 10.1177/1352458510389102 PMID: 21135023
35. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Current drug metabolism. 2002; 3(2):175-87. PMID: 12003349
36. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer research. 1990; 50(10):2863-7. PMID: 2110500
37. Hoffmann G, Wirleitner B, Fuchs D. Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflammation research: official journal of the European Histamine Research Society [et al]. 2003; 52(8):313-21. PMID: 14504669
38. Giovannoni G, Lai M, Kidd D, Thorpe JW, Miller DH, Thompson AJ, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain. 1997; 120:1-13. PMID: 9055793
39. Ott M, Demisch L, Engelhardt W, Fischer PA. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. Journal of neurology. 1993; 241(2):108-14. PMID: 8138825
40. Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta neurologica Scandinavica. 2013; 128(5):321-7. doi: 10.1111/ane.12119 PMID: 23465040
41. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. The Journal of experimental medicine. 1984; 160(1):310-6. PMID: 6429267
42. Lee MK, Xu Z, Wong PC, Cleveland DW. Neurofilaments are obligate heteropolymers in vivo. The Journal of cell biology. 1993; 122(6):1337-50. PMID: 8376466
43. Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Multiple sclerosis. 2012; 18(5):552-6. doi: 10.1177/1352458512443092 PMID: 22492131
44. Huizinga R, van der Star BJ, Kipp M, Jong R, Gerritsen W, Clarner T, et al. Phagocytosis of neuronal debris by microglia is associated with neuronal damage in multiple sclerosis. Glia. 2012; 60(3):422-31. doi: 10.1002/glia.22276 PMID: 22161990
45. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002; 122(1-2):132-9. PMID: 11777557
46. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. 1998; 64(3):402-4. PMID: 9527161
47. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004; 63(9):1586-90. PMID: 15534240
48. Bartos A, Fialova L, Soukupova J, Kukal J, Malbohan I, Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand. 2007; 116(2):100-7. PMID: 17661795
49. Ehling R, Lutterotti A, Wanschitz J, Khalil M, Gneiss C, Deisenhammer F, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Multiple sclerosis. 2004; 10(6):601-6. PMID: 15584481
50. Rittling SR. Osteopontin in macrophage function. Expert reviews in molecular medicine. 2011; 13:e15. Epub 2011/05/07. doi: 10.1017/S1462399411001839 PMID: 21545755
51. Sodek J, Ganss B, McKee MD. Osteopontin. Critical reviews in oral biology and medicine: an official publication of the American Association of Oral Biologists. 2000; 11(3):279-303.
52. Schack L, Stapulionis R, Christensen B, Kofod-Olsen E, Skov Sorensen UB, Vorup-Jensen T, et al. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the alphaXbeta2 integrin. Journal of immunology. 2009; 182(11):6943-50. doi: 10.4049/jimmunol.0900065 PMID: 19454691
53. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S. Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathology and applied neurobiology. 2005; 31(3):292-303. PMID: 15885066
54. Kivisakk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, et al. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Multiple sclerosis. 2014; 20(4):438-44. doi: 10.1177/1352458513503052 PMID: 24005026
55. Teunissen C, Menge T, Altintas A, Alvarez-Cermeno JC, Bertolotto A, Berven FS, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Multiple sclerosis. 2013; 19(13):1802-9. doi: 10.1177/1352458513488232 PMID: 23695446
56. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. doi: 10.1002/ana.22366 PMID: 21387374
57. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. PMID: 6685237
58. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009; 73(22): 1914-22. doi: 10.1212/WNL.0b013e3181c47cc2 PMID: 19949037
59. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scandinavian journal of clinical and laboratory investigation. 2002; 62(4):293-9. PMID: 12476928
60. R N. Stata tip 1: The eform() option of regress Stata Technical Journal: StataCorp LP; 2003 [cited 2003]. Available: http://www.stata-journal.com/sjpdf.html?articlenum=st0054.
61. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics. 2013; 9(2):280-99. PMID: 23543913
62. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. Journal of gastroenterology. 2005; 40(1):52-6. PMID: 15692789
63. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. European journal of haematology. 2004; 72(2):135-9. PMID: 14962251
64. Moller HJ, Aerts H, Gronbaek H, Peterslund NA, Hyltoft Petersen P, Hornung N, et al. Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scandinavian journal of clinical and laboratory investigation Supplementum. 2002; 237:29-33. PMID: 12570164
65. Etzerodt A, Rasmussen MR, Svendsen P, Chalaris A, Schwarz J, Galea I, et al. Structural basis for inflammation-driven shedding of CD163 ectodomain and tumor necrosis factor-alpha in macrophages. The Journal of biological chemistry. 2014; 289(2):778-88. doi: 10.1074/jbc.M113.520213 PMID: 24275664
66. Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PloS one. 2012; 7(11):e48370. doi: 10.1371/journal.pone.0048370 PMID: 23226202
67. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003; 61(12):1720-5. PMID: 14694036
68. Correale J. The role of microglial activation in disease progression. Multiple sclerosis. 2014; 20(10): 1288-95. doi: 10.1177/1352458514533230 PMID: 24812046
69. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell death and differentiation. 2010; 17(7):1083-91. doi: 10.1038/cdd.2009.179 PMID: 19927157
70. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. The New England journal of medicine. 1998; 338(5):278-85. PMID: 9445407
71. Fabriek BO, Van Haastert ES, Galea I, Polfliet MMJ, Döpp ED, Van Den Heuvel MM, et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia. 2005; 51(4):297-305. PMID: 15846794
72. Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008; 31:247-69. doi: 10.1146/annurev.neuro.30.051606.094313 PMID: 18558855
73. Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. Journal of neuroimmunology. 1994; 51(2):135-46. PMID: 8182113